Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
- 1 April 2001
- journal article
- review article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 38 (1), 17-23
- https://doi.org/10.1016/s1040-8428(00)00134-7
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in miceNature Genetics, 1997
- Epidermal growth factor-related peptides and their receptors in human malignanciesCritical Reviews in Oncology/Hematology, 1995
- Receptor blockade with monoclomal antibodies as anti-cancer therapyPharmacology & Therapeutics, 1994
- Antigen–specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACsNature Genetics, 1994
- Analysis of homozygous mutant chimeric mice: deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production.Proceedings of the National Academy of Sciences of the United States of America, 1993
- Germ-line transmission and expression of a human-derived yeast artificial chromosomeNature, 1993
- Reshaping human antibodies for therapyNature, 1988
- Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cellsCell, 1987
- EPIDERMAL-GROWTH-FACTOR RECEPTORS IN HUMAN BLADDER CANCER: COMPARISON OF INVASIVE AND SUPERFICIAL TUMOURSThe Lancet, 1985
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975